Alpha Teknova (TKNO) Cash from Financing Activities (2020 - 2026)
Alpha Teknova's (TKNO) quarterly Cash from Financing Activities came in at -$88000.0 in Q1 2026, down 69.23% year-on-year from -$286000.0 in Q1 2025, and down 137.84% on a QoQ basis from -$37000.0 in Q4 2025.
Alpha Teknova (TKNO) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Alpha Teknova (TKNO) has 7 years of Cash from Financing Activities data on file, last reported at -$88000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 69.23% year-over-year to -$88000.0 in Q1 2026; TTM through Mar 2026 was $115000.0, a 99.24% decrease from a year earlier, with the FY2025 full-year figure at $151000.0, down 98.99% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$88000.0, down from -$37000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for TKNO reached as high as $15.4 million in Q3 2024 and fell as low as -$621000.0 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $2.2 million across 5 years, with a median of -$28000.0 in 2025.
- Across the five-year window, Cash from Financing Activities surged 514100.0% in 2022 and sank 1272.0% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $5.1 million in 2022, then plunged by 112.08% to -$621000.0 in 2023, then surged by 85.99% to -$87000.0 in 2024, then soared by 57.47% to -$37000.0 in 2025, then tumbled by 137.84% to -$88000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$88000.0 in Q1 2026, -$37000.0 in Q4 2025, and $268000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Alpha Teknova | 278.75 Mn | 260.97 Mn | 3.78 Mn | -88,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88,000.00 |
| Mar 31, 2026 | -88,000.00 |
| Dec 31, 2025 | -37,000.00 |
| Dec 31, 2025 | -37,000.00 |
| Sep 30, 2025 | 268,000.00 |
| Sep 30, 2025 | 268,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | -52,000.00 |
| Mar 31, 2025 | -52,000.00 |
| Dec 31, 2024 | -87,000.00 |
| Dec 31, 2024 | -87,000.00 |
| Sep 30, 2024 | 15.37 Mn |
| Sep 30, 2024 | 15.37 Mn |
| Jun 30, 2024 | -47,000.00 |
| Jun 30, 2024 | -47,000.00 |
| Mar 31, 2024 | -343,000.00 |
| Mar 31, 2024 | -343,000.00 |
| Dec 31, 2023 | -621,000.00 |
| Dec 31, 2023 | -621,000.00 |